Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Suven Life Sciences Gains 10%; BSE HEALTHCARE Index Down 0.3%
Mon, 8 Jul 12:11

Suven Life Sciences Gains 10%; BSE HEALTHCARE Index Down 0.3%Image source: Sakorn BernardaSv/www.istockphoto.com

Suven Life Sciences share price has zoomed 10% and is presently trading at Rs 139.9.

Meanwhile, the BSE HEALTHCARE index is at 38,114.1 (down 0.3%).

Among the top gainers in the BSE HEALTHCARE index today are MAX HEALTHCARE INSTITUTE (up 2.0%) and GLAND PHARMA (up 1.9%).

Divis Laboratories (down 3.1%) and CAPLIN POINT (down 2.7%) are among the top losers today.

Over the last one year, Suven Life Sciences has moved up from Rs 60.6 to Rs 139.9, registering a gain of Rs 79.3 (up 131.0%).

On the other hand, the BSE HEALTHCARE index has moved up from 25,703.5 to 38,114.1, registering a gain of 48.3% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 107.6%), Cadila Healthcare (up 104.1%) and Lupin (up 99.0%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 79,897.2 (down 0.1%).

The top losers among the BSE Sensex today are Titan (down 4.0%) and MUNDRA PORT & SEZ (down 2.0%). The most traded stocks in the BSE Sensex are Tata Steel and ITC.

In the meantime, NSE Nifty is at 24,272.7 (down 0.2%). Titan and Divis Laboratories are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,479.1 to 79,897.2, registering a gain of 14,418.2 points (up 22.0%).

Suven Life Sciences Financial Update...

Suven Life Sciences net profit grew 4.0% YoY to Rs -265 million for the quarter ended March 2024, compared to a loss of Rs 276 million a year ago. Net sales declined 8.7% to Rs 24 million during the period as against Rs 26 million in January-March 2023.

For the year ended March 2024, Suven Life Sciences reported 11.2% increase in net profit to Rs -1,051 million compared to net loss of Rs 1,183 million during FY23. Revenue of the company fell 13.6% to Rs 117 million during FY24.

The current Price to earnings ratio of Suven Life Sciences, based on rolling 12 month earnings, stands at -29.0.


Equitymaster requests your view! Post a comment on "Suven Life Sciences Gains 10%; BSE HEALTHCARE Index Down 0.3%". Click here!